drugset / Trial / NCT00063206
Study Evaluating DVS-233 in Adult Outpatients With Major Depressive Disorder
Treatment
Summary
Primary: To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo. Secondary: To assess the response of subjects receiving DVS-233 SR for the clinical global evaluation, functionality, general well-being, pain, and remission (Hamilton Psychiatric Rating Scale for Depression, 17-item \[HAM-D\<sub\>17\</sub\>\] \< 7) versus those subjects receiving placebo.
Timeline
- Start
- —
- Primary completion
- 2004-05
- Completion
- 2004-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Desvenlafaxine | Other / unclassified | 100 mg | — |
| Subject | Desvenlafaxine | Other / unclassified | 200 mg | — |